Lunai Bioworks (NASDAQ: LNAI), an AI-powered drug discovery and biodefence company, on Wednesday announced the publication of a landmark study detailing its second-generation allogeneic dendritic cell (DC) therapy platform in the peer-reviewed journal Vaccines (2 November 2025). The new therapy achieved complete regression of both primary and metastatic pancreatic tumours in preclinical humanised mouse models.

The publication describes a clinical-grade, next-generation DC construct designed to activate the immune system against hard-to-treat cancers such as pancreatic cancer. The optimised, compliant version maintains the efficacy of Lunai's earlier research-grade platform while incorporating enhanced genetic elements and manufacturing improvements to support clinical translation.

In preclinical testing, the engineered DCs - derived from CD34+ hematopoietic stem cells and modified to express CD40L, CD93, and CXCL13 - elicited strong activation of cytotoxic T cells and natural killer cells, leading to full tumour regression. These results reinforce the potential of Lunai's platform to address a broad spectrum of solid tumours beyond pancreatic cancer.

This new work builds on Lunai's previously published study (Vaccines 2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749), advancing the company's progress toward clinical development and strategic partnerships.

Lunai Bioworks combines proprietary neurotoxicity datasets, machine learning and responsible generative biology to accelerate therapeutic discovery while managing dual-use risks in biodefence and biomedicine.